Key facts
- Pheast Therapeutics’s last known valuation is $154.6M (Oct 2025).
- It has raised $100.6M across 2 recorded rounds; the latest was Early Stage VC ($24.6M) in Oct 2025.
- Notable investors include Alexandria Venture Investments, ARCH Venture Partners, Catalio Capital Management, Rsquared.
- Pheast Therapeutics has filed 2 Form Ds with the SEC since 2022, most recently Apr 2025 ($75.3M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Pheast Therapeutics
Funding rounds
2 roundsAbout Pheast Therapeutics
Provider of immuno-oncology therapies intended to activate the innate immune system to fight cancer. The company offers an anti-CD24 macrophage checkpoint inhibitor engineered to induce macrophages to engulf and destroy cancer cells, alongside additional therapies for aggressive cancers, enabling patients with hard-to-treat tumors to benefit from targeted immune activation.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2021
- Employees
- 33
- Website
- pheast.com/
- Ownership
- Privately Held (backing)
Pheast Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pheast Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pheast Therapeutics in its N-PORT filings yet. We sweep new filings monthly.